The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including ocular diseases or disorders, skin diseases or disorders, certain cancers, particularly intraluminal cancers, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases/disorders and rheumatic diseases/disorders.

The present application relates to nutritional compositions comprising lactic acid-producing bacteria.

Described herein are novel compositions comprising a cannabis component selected from the group consisting of: a cannabinoid, a flavonoid and a terpenoid; and a protein, selected from the group consisting of whey and a plant protein. According to an embodiment, the cannabis component is non-covalently bound to the whey or to the plant protein. The plant protein may be selected from the group consisting of: soy protein, pea protein, rice protein, hemp protein, and hops protein or other plant derived protein.

The present invention relates to the use of collagen hydrolysate for improving endurance performance by increasing mitochondrial activity. Further, the invention relates to the use of collagen hydrolysate for stimulating lipid catabolism, and in particular for reducing body weight, by increasing mitochondrial activity.

Compositions and methods for providing infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins.

The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.

Methods and compositions for providing control over a subject's body, include methods and compositions for enhancing the ability of a subject's body to lose weight, or for inducing weight loss in the subject's body. Such methods and compositions may induce thermogenesis in the adipocytes of a subject's body, enhancing the subject's metabolism, inhibit adipogenesis in adipocytes of the individual, and reduce the subject's cravings for food, the subject's appetite and/or the amount of food consumed by the subject. Such a composition may include African mango (Irvinia gabonensis) seed extract, citrus fruits extract from Citrus aurantium, Citrus sinensis, and/or Citrus paradisi (standardized to 5% synephrine and 80% bioflavonoids), Coleus forskholi root extract, and a source of dihydrocapsiate. The composition may be administered with a protein supplement, such as a whey protein supplement (e.g., a hydrolyzed whey protein supplement).

A problem of the present invention is to provide a skin collagen production-promoting agent without safety problems. Another problem of the present invention is to provide a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product containing such a substance. TGF-β and/or a TGF-β degradation product, which is acquired by degrading TGF-β with a protease such as pepsin, pancreatin, etc., are used as a skin collagen production-promoting agent or the active ingredient of a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product. The aforementioned TGF-β and/or TGF-β degradation product have an effect of increasing the collagen content of the skin.

Provided herein is a method of reducing postprandial concentrations of glucose in a subject's blood comprising administering to the subject, prior to or during a meal, an effective amount of a combination of a marine peptide and a fish nucleotide, sufficient to reduce the glucose concentration in the subject's blood. Further provided herein is a method of reducing postprandial concentration of ghrelin in a subject's blood, comprising administering to the subject, prior to or during a meal, an effective amount of a combination of a marine peptide and a fish nucleotide sufficient to increase the blood component wherein the combination is administered to the subject.

This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.